title: Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
abstract: Anti-cholinergic drugs are used in the treatment of Parkinson’s disease (PD) and they can improve motor disability in some patients and may alter the expression of dyskinesia. We report the effects of anticholinergic and pro-cholinergic agents administered alone and combined with L-DOPA, on motor function in 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Administration of atropine to MPTP-treated marmosets, not previously exposed to L-DOPA, improved motor disability but this did not occur with other centrally acting anti-cholinergics. Motor disability was worsened by centrally acting pro-cholinergics. However, neither peripherally acting anti- nor pro-cholinergics produced any effect on motor disability or dyskinesia. In MPTP-treated marmosets previously primed with L-DOPA to exhibit dyskinesia, acute L-DOPA challenge induced both chorea and dystonia. In these animals, centrally acting anti-cholinergics including atropine and trihexyphenidyl reversed motor deficits, but induced chorea. Combined with L-DOPA, both centrally and peripherally acting anti-cholinergics reduced peak locomotor activity and produced more chorea than dystonia compared to L-DOPA alone. Centrally acting pro-cholinergics decreased locomotor activity, worsened motor disability and induced dystonia. Co-administered with L-DOPA, pro-cholinergics reduced locomotor activity and decreased chorea while increasing dystonia compared with L-DOPA alone. In conclusion, anti-cholinergics can increase chorea with and without L-DOPA but improve motor disability. Pro-cholinergics decrease the proportion of chorea when combined with L-DOPA, increase motor disability and antagonise L-DOPA’s effectiveness. These data suggest that there may be a case for revisiting the use of anti-cholinergic drugs in the treatment of PD.
authors: M J
authors: MJ
authors: Jackson
authors: T
authors: T
authors: Swart
authors: R K B
authors: RK
authors: Pearce
authors: P
authors: P
authors: Jenner
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002144:Callithrix; D002230:Carbidopa / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D007980:Levodopa / Q000009:adverse effects*; D020267:MPTP Poisoning / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D018709:Statistics, Nonparametric
chemical_list: D000978:Antiparkinson Agents; D018678:Cholinergic Agents; D007980:Levodopa; D002230:Carbidopa
references: Zhongguo Yao Li Xue Bao. 1994 May;15(3):235-9
references: 7976378
references: Adv Neurol. 1984;40:131-40
references: 6695589
references: Psychopharmacology (Berl). 1990;102(3):295-300
references: 1979176
references: J Pharmacol Exp Ther. 1975 Feb;192(2):451-7
references: 1117428
references: Cochrane Database Syst Rev. 2003;(2):CD003735
references: 12804486
references: Eur J Pharmacol. 1983 Nov 11;95(1-2):65-70
references: 6141945
references: Psychopharmacology (Berl). 1988;96(1):55-62
references: 2906443
references: Neuroscience. 1989;28(3):611-23
references: 2710334
references: Eur J Pharmacol. 1976 Feb;35(2):293-9
references: 1248506
references: J Comp Neurol. 1992 Sep 8;323(2):252-68
references: 1401259
references: Psychopharmacology (Berl). 1993;111(4):435-41
references: 7870985
references: Clin Neuropharmacol. 1991 Apr;14(2):148-55
references: 2015611
references: Neurology. 1982 Aug;32(8):889-92
references: 6124899
references: Mov Disord. 1995 Nov;10(6):731-40
references: 8749992
references: Neurology. 1996 Apr;46(4):1051-4
references: 8780089
references: Annu Rev Neurosci. 1983;6:73-94
references: 6838141
references: Prog Brain Res. 1993;99:155-65
references: 8108546
references: Mov Disord. 2011 Oct;26 Suppl 3:S2-41
references: 22021173
references: Naunyn Schmiedebergs Arch Pharmacol. 1994 May;349(5):523-7
references: 8065466
references: Clin Neuropharmacol. 1993 Oct;16(5):418-27
references: 8106150